4 Healthcare Stock Stories for Investor Wellbeing

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Johnson & Johnson (NYSE:JNJ): Closing price $72.35

On Thursday, an FDA advisory panel okayed J&J’s canagliflozin, a drug for diabetes that could be the first in a new class of domestic drugs to treat the disease, although several panel members were worried about potential cardiovascular risks and its use in people whose kidneys are impaired. The panel voted 10 to 5, for approval. The drug is part of a new group of drugs that reduces blood sugar by causing blood sugar to be excreted through the urine. Many current treatments work by affecting the supply or use of insulin.


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business